If you'd like your company to be on this list please contact us
Select a name to see a detailed description, expert analysis and contact information.
|"INO continues to advance multiple immunotherapy studies forward, which should provide incremental catalysts for the stock as data emerges."|
|"RVX remains gravely undervalued at the current share price."|
|"Based on RXI's new checkpoint inhibitors and the potential for multiple partnering deals, we are maintaining our Buy recommendation."|
|"We initiate with an Outperform on VIVE."|
|"We continue to be optimistic about DRRX's story."|